Vaginal inserted estradiol pharmaceutical compositions and methods
DCFirst Claim
Patent Images
1. A method for treating moderate to severe dyspareunia in a human subject comprising:
- intravaginally administering estradiol to the subject by manually inserting about two inches into the vagina a liquid pharmaceutical composition comprising about 4 μ
g to about 25 μ
g of estradiol, wherein the composition has a viscosity from about 50 cP to about 1000 cP at 25°
C., wherein the composition comprises all of the estradiol and is encapsulated in a capsule, and wherein the composition is inserted while the subject is in a reclining position or in a standing position;
wherein administration of the composition results in a decrease in the severity of moderate to severe dyspareunia in the subject within two to six weeks from the first administration.
9 Assignments
Litigations
0 Petitions
Accused Products
Abstract
In one aspect, compositions and methods for the treatment of vulvovaginal atrophy (VVA) are provided. In one embodiment, the method comprises administering an estrogen to a subject having VVA by inserting a dosage form comprising a liquid pharmaceutical composition.
1217 Citations
10 Claims
-
1. A method for treating moderate to severe dyspareunia in a human subject comprising:
-
intravaginally administering estradiol to the subject by manually inserting about two inches into the vagina a liquid pharmaceutical composition comprising about 4 μ
g to about 25 μ
g of estradiol, wherein the composition has a viscosity from about 50 cP to about 1000 cP at 25°
C., wherein the composition comprises all of the estradiol and is encapsulated in a capsule, and wherein the composition is inserted while the subject is in a reclining position or in a standing position;wherein administration of the composition results in a decrease in the severity of moderate to severe dyspareunia in the subject within two to six weeks from the first administration. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10)
-
Specification